ReviewStem cell reviews and reports2026
Stem Cells and their Key Derivatives in Degenerative Musculoskeletal Diseases.
Review in Stem cell reviews and reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Extracellular vesicles for next-gen therapeutics and drug delivery.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Degenerative musculoskeletal diseases such as osteoporosis (OP), osteoarthritis (OA), and intervertebral disc degeneration (IVDD) represent a growing global health challenge, causing disability, pain, and socioeconomic burden. Traditional therapies remain largely palliative, underscoring the urgent need for regenerative approaches. Mesenchymal stem cells (MSCs) are promising tools due to their capacity for multilineage differentiation, immunomodulation, and paracrine signaling. However, challenges including heterogeneity, low engraftment, and manufacturing complexity limit their clinical translation. Increasingly, extracellular vesicles (EVs) derived from MSCs have been recognized as the principal mediators of their therapeutic effects. MSC-derived-EVs (MSC-EVs) provide a safer, cell-free platform capable of regulating immune responses, promoting tissue regeneration, and delivering bioactive cargos that restore bone, cartilage, and disc homeostasis. Preclinical and early clinical data highlight their potential as next-generation therapeutics. The aim of this review is to provide valuable insights into the development and evaluation of MSCs and MSC-EVs in OA, OP, and IVDD thereby accelerating clinical translation and improving patient outcomes.
Indexed as
Identifiers
41793557What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.